Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Weeks 13 and beyond: full therapeutic effect At 12mg weekly maintenance, you are at the dose that produced the headlines
Repeat Customer 5 mo ago Second order and it went just as smoothly as the first
doi: 10.3390/molecules26175377 46 PiettaPG
Liraglutide and semaglutide have beneficial effects on non-alcoholic steatohepatitis.200,201 Additionally, incretin mimetic drugs targeting multiple receptors for greater efficacy, including glucagon and GIP receptors, are under development.202 A Phase 2a study of efocipegtrutide (HM15211), a new long-acting triple GLP-1/GIP/glucagon RA is currently being conducted to assess its use to treat non-alcoholic steatohepatitis.203 Survodutide, a novel dual GLP-1/ glucagon RA, significantly reduced body weight and improved metabolic dysfunction-associated steatohepatitis compared to the placebo in phase II trials.204 Mazdutide, a dual GLP-1/glucagon RA, and retatrutide, a triple GLP-1/GIP/glucagon RA, also have both shown significant weight loss effects in Phase 2 trials.205,206 Among the drugs discussed, including US FDA-approved GLP-1 RAs, tirzepatide was reported to achieve the most significant reduction in blood glucose levels
Active Ingredient: Copper Peptide (GHK-Cu) Available in 50 mg Inactive Ingredients: Lyophilized powder without preservatives GHK-Cu Vials: Quantity and dosage based on selected package Antibacterial Water: Equal number of 2 ml vials for reconstitution Test Certificate: Included to confirm product purity and quality GHK-Cu 5 out of 5 based on 1 customer rating EUR 66.46 EUR 66.46 EUR 66.46 sample GHK is a premium copper-binding tripeptide available in 20 mg and 50 mg lyophilized powder options
